AMS INSIGHT 1 Study - Bioabsorbable Metal Stent Investigation in Chronic Limb Ischemia Treatment

NCT00572494 | Completed Phase 2 DMC

• 1 other identifier: BIOTRONIK Reference 27-1
• Study Type: interventional
• Target: 117
• Locations: 4 countries
• Sites: 12

Brief Summary

Prospective, multicenter, randomized clinical trial, Follow-up at 1-, 6- and 12 months This clinical investigation is first of all designed to demonstrate the safety and effectiveness of the MAGIC EXPLORER stent system. The primary objectives of the study are to evaluate the safety and 6-month patency of the bioabsorbable MAGIC EXPLORER stent in patients with stenotic or occlusive atherosclerotic disease of the infrapopliteal arteries. Secondary endpoints are the procedural success, patency at all follow-ups, late lumen loss and limb-salvage rate. Peri-procedural complications (within 24 hours) will be evaluated. Furthermore, data of the balloon catheter PLEON EXPLORER will be collected to demonstrate its effectiveness and safety.

Conditions

Peripheral Artery Disease

Keywords

Tibial arteries; Absorbable implants; Stents; Limb salvage

Outcome Measures

Primary Outcomes (2)

• Efficacy : patency of the AMS, defined as the absence of a hemodynamically significant restenosis (> 50%)

  6 month

• Safety: Complications at 1 month post-procedure (major amputations or any cause of death)

  1 month

Secondary Outcomes (4)

• Immediate angiographic procedural success, defined as maximal 30% residual stenosis on visual assessment of the planned treatment area.

  procedure

• Patency at follow-up visits determined with Color Flow Doppler Ultrasound (CFDU)

  1 & 6 months

• Late lumen loss at 6 months.

  6 months

• Limb-salvage rate at follow-up visits, defined as lack of major amputation.

  1 & 6 months

Study Arms (2)

1

EXPERIMENTAL

Stenting with AMS

Device: MAGIC EXPLORER (Biotronik AG)

2

ACTIVE COMPARATOR

PTA alone

Device: PLEON EXPLORER (Biotronik AG)

Interventions

MAGIC EXPLORER (Biotronik AG) DEVICE

The lesion is pre-dilated with the PLEON EXPLORER balloon with a length of 10 mm or 15 mm or 20 mm under angiographic control. After dilation, the stenosed area is treated by one AMS implant. If the implanted stent is not fully apposed to the vessel wall or if initial angiography reveals a residual stenosis, the stent may be post-dilated with the delivery system balloon. If necessary, a high-pressure, non-compliant balloon catheter may be used.

1

PLEON EXPLORER (Biotronik AG) DEVICE

The lesion is dilated with the PLEON EXPLORER balloon with lengths of 10 mm or 15 mm or 20 mm, respectively. In case that the PTA procedure results in a residual stenosis of \>50%, the AMS implant should be used to improve the result. A flow-limiting dissection does not qualify for stenting. Best effort must be made to obtain a satisfactory result (e.g. multiple and prolonged inflations) before a patient in the PTA group can be treated with a stent.

2

Eligibility Criteria

• Age: 50 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Stenotic (\> 50%) or occlusive atherosclerotic disease of the infrapopliteal arteries
• Length of lesion \< 20mm (less than one stent length)
• Reference vessel diameter should be 3.0-3.5 mm
• A maximum of two lesions in one infrapopliteal vessel treated within the study, or in two vessels of two different legs. (PTA treatment of other infrapopliteal lesions in non-study vessels is allowed outside the study).
• Symptomatic critical limb ischemia (Rutherford 4, 5)
• The patient must be ≥ 50 years.
• Life-expectancy of more than 6 months
• The subject or legal guardian has been informed of the nature of the study; agrees to its provisions and has signed informed consent
• The patient must be available for the appropriate follow-up times for the duration of the study
• The patient is capable to follow all study requirements.

You may not qualify if:

• Patient refusing treatment
• The reference segment diameter is not suitable for available stent design
• Length of lesion requires more than one stent implantation
• Previously implanted stent(s) or PTA at the same lesion site
• Lesion lies within or adjacent to an aneurysm
• Inflow-limiting arterial lesions left untreated
• The patient has a known allergy to heparin, Aspirin or other anticoagulant/antiplatelet therapies or a bleeding diatheses or is unable, or unwilling, to tolerate such therapies.
• The patient takes Phenprocoumon (Marcumar).
• The patient has a history of prior life-threatening contrast media reaction.
• The patient is currently enrolled in another investigational device or drug trial.
• The patient is currently breast-feeding, pregnant or intends to become pregnant.
• The patient is mentally ill or retarded.
• The patient is liable for military or civilian service.

Sponsors & Collaborators

• Flanders Medical Research Program: lead
• Biotronik SE & Co. KG: collaborator

Study Sites (12)

Medizinische Universität Graz

Graz, Austria

Location

A.ö. Landeskrankenhaus Klagenfurt

Klagenfurt, Austria

Location

Allgem. Krankenhaus Vienna

Vienna, Austria

Location

Universitair Ziekenhuis Antwerpen

Antwerp, Belgium

Location

Imelda Ziekenhuis Bonheiden

Bonheiden, Belgium

Location

AZ St-Blasius

Dendermonde, 9200, Belgium

Location

Herzzentrum Bad Krozingen

Bad Krozingen, Germany

Location

Humaine Kliniken Bad Saarow

Bad Saarow, Germany

Location

Ev. Krankenhaus Herberge Berlin

Berlin, Germany

Location

Universitätsklinikum Leipzig

Leipzig, Germany

Location

Universitätsklinikum Mainz

Mainz, Germany

Location

Sint-Elisabeth Ziekenhuis Tilburg

Tilburg, Netherlands

Location

MeSH Terms

Conditions

Peripheral Arterial Disease

Condition Hierarchy (Ancestors)

Atherosclerosis; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Cardiovascular Diseases; Peripheral Vascular Diseases

Study Officials

• Marc Bosiers, MD

  AZ Sint-Blasius, Dendermonde, Belgium

  PRINCIPAL INVESTIGATOR

• Evelyn Diessel, PhD

  Biotronik SE & Co. KG

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: NETWORK

Study Record Dates

• First Submitted: December 12, 2007
• First Posted: December 13, 2007
• Study Start: July 1, 2005
• Study Completion: January 1, 2007
• Last Updated: February 8, 2008

Record last verified: 2008-02

Locations

NL (1); DE (5); AU (3); BE (3)